Joint infiltration is the precise, image-guided delivery of a regenerative or biologic substance directly into the joint capsule — knee, hip, shoulder, ankle, facet, sacroiliac, or small joints of the hand and foot. The technique sounds simple. Done well, it is not: the difference between a needle that lands inside the synovial cavity and one that deposits the product in surrounding fat or capsule is the difference between a real response and a wasted treatment. At Regeneris Therapy every joint infiltration is performed under ultrasound or fluoroscopic guidance by physicians trained in interventional musculoskeletal medicine. We deliver mesenchymal stem cells, PRP, hyaluronic acid, or medical ozone — sometimes in combination — and we are honest about what an intra-articular injection can and cannot accomplish. Here is the plain-language explanation.
What joint infiltration actually is
Joint infiltration — also called intra-articular injection — is the targeted introduction of a therapeutic substance into the synovial cavity of a joint. Every joint has a closed capsule lined with synovial membrane that secretes synovial fluid; this is the space we are aiming for. When the needle is placed correctly, the injected substance distributes throughout the joint surfaces, the synovium, and the immediate sub-synovial tissue — exactly the compartments where degenerative or inflammatory processes are occurring. When the needle misses the cavity and lands in fat, ligament, or capsule, almost none of the product reaches its target. That is why image guidance is not optional in modern practice. Joint infiltration is performed routinely on the knee, hip, glenohumeral (shoulder), acromioclavicular, ankle, subtalar, facet (spinal) joints, sacroiliac joints, and the smaller joints of the hand, wrist, and foot. Each location has its own anatomical considerations and its own ideal approach.
Substances we deliver: MSC, PRP, hyaluronic acid, medical ozone
Our intra-articular menu is tailored to the indication. Mesenchymal stem cells from licensed COFEPRIS-registered laboratories (Wharton's jelly UC-MSC) or prepared chairside as autologous BMAC or SVF are reserved for moderate degenerative disease where regenerative signaling is the goal — see stem cell therapy. Platelet-rich plasma drawn and processed the same day is our workhorse for mild-to-moderate joint OA, partial cartilage lesions, and adjunctive use with MSC — details on PRP therapy. Hyaluronic acid (viscosupplementation) restores synovial fluid viscosity and is useful for symptomatic relief in knee OA, particularly when patients want a less expensive option before stepping up to biologics. Medical ozone (oxygen-ozone gas mixture) has anti-inflammatory and oxidative-stress-modulating effects and is used as a low-cost adjunct in selected indications. We do not push the most expensive product. We match the substance to your case and explain why.
When intra-articular makes sense versus IV delivery
This is one of the most important conversations we have with patients considering regenerative medicine, and one many clinics skip. Intra-articular delivery puts the therapeutic dose directly where the problem is — useful for focal, mechanical, localized joint disease such as a single painful knee or shoulder. IV delivery, by contrast, distributes cells systemically through the bloodstream and is the right route for autoimmune, inflammatory, longevity, or multi-site indications where a systemic immunomodulatory effect is the goal. The two routes are not interchangeable. A patient with a single arthritic knee usually benefits more from a targeted intra-articular injection than from a systemic IV. A patient with lupus, fibromyalgia, or Long COVID needs the IV route. Some cases benefit from both — for example, a patient with bilateral hip OA and a systemic inflammatory component may receive an IV infusion plus targeted intra-articular injections at the same visit. We decide route based on biology, not on what costs more.
Image-guided versus blind: we use ultrasound or fluoroscopy
A 'blind' joint injection — placed by palpation and surface landmarks alone — has a published accuracy in the range of 30–80% depending on the joint and the operator. The knee and shoulder are at the higher end; the hip, sacroiliac, and small joints are at the lower end. That means a substantial fraction of blind injections do not reach the intended target, which silently undermines outcomes and leads patients to wrongly conclude that the therapy 'did not work.' Every infiltration at our clinic is performed under real-time ultrasound guidance or, when appropriate (deep facet joints, hip joint in larger patients, some sacroiliac cases), fluoroscopic guidance. Ultrasound is the workhorse: it visualizes needle, anatomy, and product distribution in real time without radiation. Fluoroscopy is used selectively when bony landmarks are the better target reference. Image guidance is not a premium add-on — it is the standard, and it is what allows us to commit to real, measurable outcomes.
Joints we treat
We perform regenerative joint infiltrations on essentially every accessible synovial joint. The knee is by far the most common indication and is well-supported by published evidence — see our knee treatment page and the knee osteoarthritis condition page. Hip OA, shoulder OA and rotator cuff tendinopathy, ankle and subtalar arthritis, lumbar facet joints, sacroiliac joint dysfunction, thumb basal joint (CMC) arthritis, and toe joints (hallux rigidus) are all treated routinely. We do not infiltrate every joint at every visit — we map your symptoms to specific anatomical structures and target the joints that are actually generating the pain. Diagnostic ultrasound at the time of consultation often reveals that the joint patients suspect is not the only — or even the main — source of their symptoms.
Realistic outcomes: pain reduction and function, not cartilage rebuild
This is the section we ask every patient to read carefully. Intra-articular regenerative injections — whether PRP, MSC, hyaluronic acid, or combinations — produce meaningful clinical effects: pain reduction, improved range of motion, better walking distance, longer pain-free intervals, reduced reliance on analgesics, and in many cases delayed or avoided joint replacement surgery. They do not, in any human study, demonstrably rebuild full-thickness cartilage. The honest mechanism is anti-inflammatory and biological-environment improvement, not cartilage regrowth. For mild-to-moderate OA (Kellgren-Lawrence grades 1–3), realistic pain reductions are 40–70% with functional gains lasting 12–24 months and the option to retreat. For severe (grade 4) OA with bone-on-bone contact, intra-articular injections offer at best modest, short-term symptom relief and are not a substitute for surgical consultation. We will tell you which category you are in honestly. We do not sell injections that will not help you.
Safety profile and sterile technique
Image-guided intra-articular injections performed under sterile technique have a very low complication rate. The most common side effect is a transient post-injection flare — increased pain in the joint for 24–72 hours after the procedure, particularly with PRP — which resolves with rest and ice. Serious infections (septic arthritis) are exceedingly rare in published series when sterile preparation is observed: a single-digit per ten thousand rate in well-conducted studies. Our clinic uses single-use sterile injection kits, chlorhexidine or povidone skin preparation, sterile drapes, and dedicated procedure rooms. Patients on anticoagulation, with active joint infection, or with uncontrolled diabetes require additional considerations and are discussed individually. There is no fluoroscopy contraindication for routine intra-articular work — radiation exposure is minimal — but we reserve fluoroscopy for cases where it adds genuine diagnostic value.
When to combine with PRP, exosomes, or systemic therapy
Combination is often the right answer for moderate disease. A common protocol is an intra-articular MSC injection followed by 2–3 monthly PRP boosters, which extends the inflammatory-modulation window and supports tendon and ligament structures around the joint. Some cases benefit from intra-articular MSC plus exosome support delivered the same session — exosomes are smaller and may penetrate cartilage matrix more effectively than whole cells. Patients with a systemic inflammatory component (autoimmune disease, post-viral inflammation) often do better with an IV MSC infusion alongside their intra-articular work; the systemic anti-inflammatory effect reduces the catabolic environment that drives joint deterioration. The point is that combinations are individualized, not packaged. Start your evaluation at a regenerative medicine consultation.
Talk to our team about whether a targeted joint infiltration is the right next step for your specific joint, your imaging findings, and your goals.
